Legal Representation
Attorney
Chang Sik Lim
USPTO Deadlines
Next Deadline
87 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
October 03, 2025
Extension Available
Until October 03, 2024
Application History
26 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 3, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Apr 2, 2025 | EXT3 | S | SOU EXTENSION 3 FILED |
| Apr 2, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 1, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 1, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Oct 1, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 1, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 2, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Apr 2, 2024 | EXT1 | S | SOU EXTENSION 1 FILED |
| Apr 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 3, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Aug 8, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 8, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jul 19, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 2, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jun 2, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jun 1, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 1, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Dec 1, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Dec 1, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Dec 1, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Nov 30, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 22, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 19, 2022 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
biopharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; biologic preparations for the treatment of cancer; biologic preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; pharmaceutical preparations and substances for use in oncology treatment; pharmaceuticals for the treatment of cancer; prescription pharmaceuticals for treatment of diseases and disorders, namely, cancer and chronic diseases
Class 044
Providing health and medical information about medical disorders and their diagnosis, prevention and treatment; information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, including pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services; information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, including pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services provided on-line over a computer network and the Internet; Providing information regarding medical conditions; medical information services; providing medical information regarding testing, diagnosis, and treatment of diseases; providing medical information to patients regarding disease management and medication
Additional Information
Design Mark
The mark consists of the term CG PHARMACEUTICALS in a stylized format.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"